Seer Inc.'s Special Committee has unanimously rejected an unsolicited acquisition offer from CEO and founder Omid Farokhzad. The non-binding proposal, received on July 1, 2026, sought to purchase all outstanding Class A shares at $2.45 per share plus two contingent value rights. The committee determined the offer undervalued the company's potential and long-term prospects. Seer continues to manufacture proprietary proteomics technology, including the Proteograph suite used in research workflows. Shares closed Friday at $2.17, down 1.46%, and fell a further 1.84% in pre-market trading to $2.13.
Seer IncCEO's acquisition bid rejected as undervaluing the company, indicating no immediate premium for shareholders; shares fell in pre-market.